WINSTON-SALEM, N.C., Jan. 13, 2014 (GLOBE NEWSWIRE) -- Tengion, Inc. (OTCQB:TNGN), a leader in regenerative medicine, today announced continued clinical progress in its two lead programs, the Neo-Kidney Augment and the Neo-Urinary Conduit.
Help employers find you! Check out all the jobs and post your resume.
